- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02999074
Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (BENEFIT)
A Randomized 3-arm Exercise Intervention Trial for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
The BENEFIT-Study is a randomized controlled 3-arm intervention trial investigating the currently discussed hypothesis that exercise concomitant to chemotherapy (CTx) may have a beneficial effect on cancer prognosis by boosting the anti-tumoral effect of the cytostatics or by enhancing therapy compliance. This hypothesis is based on pre-clinical and exploratory clinical trials. Breast cancer patients scheduled for neoadjuvant CTx will be randomized to either a resistance training or an aerobic training concomitant to the neoadjuvant CTx, or a waiting list control group that will get no exercise intervention during neoadjuvant CTx (i.e. usual care) but will exercise after breast surgery. The primary study endpoint is the tumor size. Further, the effects of resistance and aerobic exercise on the clinical-pathologic stage (CPS-EG) score, the pathological complete response (pCR), tolerability and compliance to CTx, physical fitness, patient reported outcomes such as fatigue, sleep problems, quality of life, depressive symptoms, anxiety and pain, as well as cognitive function, and selected biomarkers will be investigated.
A confirmation of the study hypothesis would be a strong argument for patients to engage in exercise as early as during neoadjuvant CTx. The trial will also provide evidence-based guidance for patients regarding type and timing of training.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Martina E Schmidt, Dr.
- Phone Number: +49 6221 42 2220
- Email: m.schmidt@dkfz.de
Study Contact Backup
- Name: Karen Steindorf, Prof. Dr.
- Phone Number: +49 6221 42 2351
- Email: k.steindorf@dkfz.de
Study Locations
-
-
-
Heidelberg, Germany, 69120
- National Center for Tumor Diseases (NCT)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women ≥ 18 years of Age
- Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy
- Scheduled for neoadjuvant CTx (but not yet started)
- Confirmed hormone receptor and Her2 status
- Sufficient German language skills
- Willing to train at the exercise facilities twice per week
Exclusion Criteria:
- Any physical or mental conditions that would hamper the adherence to the training programs or the completion of the study procedures
- Engaging in systematic intense exercise training (at least 1h twice per week)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Aerobic exercise
|
The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists.
The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration.
During weeks 7-18 the goal is to perform an extensive interval training.
|
Active Comparator: Resistance exercise
|
The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists.
The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
|
Other: Waitlist control
|
The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition.
To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor size
Time Frame: change from baseline (before start of neoadjuvant chemotherapy) to breast surgery
|
percentage of change from the maximal diameter of the lesion assessed before neoadjuvant chemotherapy (by mammography or sonography) to the maximal diameter of the tumor assessed after neoadjuvant chemotherapy at breast surgery
|
change from baseline (before start of neoadjuvant chemotherapy) to breast surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CPS-EG score
Time Frame: at breast surgery
|
The Clinical-Pathologic Stage (CPS-EG) score combines clinical tumor stage prior to neoadjuvant therapy (CS), pathological tumor stage after neoadjuvant treatment (PS), estrogen receptor status (E) and grading (G).
It has been shown to be a valid prognostic factor to discriminate among patient subgroups with respect to survival after neoadjuvant CTx.
|
at breast surgery
|
pCR
Time Frame: at breast surgery
|
The Pathological Complete Response (pCR) is defined as ypT0/is ypN0 and has been consistently demonstrated to be a good prognostic factor for long-term benefit from neoadjuvant CTx.
|
at breast surgery
|
Fatigue Assessment Questionnaire (FAQ)
Time Frame: at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Validated 20-item multidimensional self-assessment questionnaire to assess the physical, affective, and cognitive dimension of cancer-related fatigue
|
at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
EORTC QLQ-C30 / BR23
Time Frame: at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Validated 30-item self-assessment questionnaire to assess quality of life aspects.
|
at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Patient Health Questionnaire for Depression and Anxiety (PHQ-4)
Time Frame: at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
A validated 4-item screener for depression and anxiety.
|
at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Validated questionnaire to assess sleep quality and sleep problems.
|
at baseline, week 9, post-chemotherapy (before breast surgery); months 6 and 12 after breast surgery
|
Spiroergometry (VO2max)
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
|
Isometric and isokinetic muscle strength measured by ISOMED 2000
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
|
Body mass index
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
|
Self-developed physical activity questionnaire including type, duration, frequency and intensity of sports, cycling,and walking
Time Frame: Follow-up (6 months and 12 months after breast surgery)
|
Follow-up (6 months and 12 months after breast surgery)
|
|
Cognitive function - HVLT-R
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Hopkins Verbal Learning Test - Revised (HVLT-R)
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Cognitive function - TMT
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Trail Making Test
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Cognitive function - COWA
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Controlled Oral Word Association
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Sleep quality
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Measured with ActiGraph (accelerometry)
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Sleep efficiency
Time Frame: at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Measured with ActiGraph (accelerometry)
|
at baseline, post-chemotherapy (before breast surgery); month 6 after breast surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BENEFIT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Resistance exercise
-
Universidade Federal de PernambucoUnknownChikungunya FeverBrazil
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension | Healthy
-
Iowa State UniversityCompletedCardiovascular Risk Factor
-
University of AlbertaDexCom, Inc.CompletedType 1 DiabetesCanada
-
VA Office of Research and DevelopmentRecruiting
-
Mekelle UniversityCompleted
-
University of Central FloridaCompletedHealthyUnited States
-
National Taiwan Normal UniversityCompletedExecutive FunctionTaiwan
-
University of AlbertaCompletedType 1 DiabetesCanada